The A4 Study
A Phase III study of the drug solanezumab

Who may be eligible to participate?

Individuals 65-85 years of age with normal cognition.

Participants must have a reliable study partner: a spouse, relative, or friend who knows the participant well and sees him or her often, who will attend some study visits, and who will provide information about the participant during the study.

Eligibility is determined through a two-stage process. An initial screening visit to determine normal cognition includes:

- A physical/neurological exam
- Medical history
- Medication review
- Collection of blood and urine (a 10-hour fast prior is required)
- Tests of memory and thinking

If normal cognition is determined, then a second screening visit to measure levels of brain amyloid will include:

- PET scan to measure brain amyloid
- Electrocardiogram (ECG)
- Brain MRI
- Optional Lumbar Puncture

After the screening, study activity includes:

- Infusion visits every four weeks, for a total of 42 infusion visits over three consecutive years at the Clinical Translational Research Center at the Hospital of the University of Pennsylvania.
  
  - Participants are reimbursed $39 for each visit.

- Before enrolling, the participant and study partner must read, understand, and sign a formal consent form which fully explains the study.

For more information, contact
Study Coordinator
Jessica Nuñez 215-662-4379
jessica.nunez@uphs.upenn.edu